Regeneron Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, understanding spending patterns can offer insights into a company's strategic priorities. Over the past decade, Regeneron Pharmaceuticals, Inc. and Geron Corporation have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.

Regeneron, a leader in the biotech industry, has consistently increased its SG&A spending, growing from approximately $505 million in 2014 to a staggering $2.63 billion in 2023. This represents a more than fivefold increase, reflecting its aggressive expansion and market penetration strategies. In contrast, Geron Corporation's SG&A expenses have grown at a more modest pace, from around $16.8 million in 2014 to $69.1 million in 2023, a fourfold increase.

These spending patterns highlight Regeneron's robust growth trajectory compared to Geron's more conservative approach, offering a fascinating glimpse into their respective business strategies.